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OBJECTIVE—The efﬁcacy of liraglutide, a human glucagon-like
peptide-1 (GLP-1) analog, to prevent or delay diabetes in UCD-
T2DM rats, a model of polygenic obese type 2 diabetes, was
investigated.
RESEARCH DESIGN AND METHODS—At 2 months of age,
male rats were divided into three groups: control, food-re-
stricted, and liraglutide. Animals received liraglutide (0.2 mg/kg
s.c.) or vehicle injections twice daily. Restricted rats were food
restricted to equalize body weights to liraglutide-treated rats.
Half of the animals were followed until diabetes onset, whereas
the other half of the animals were killed at 6.5 months of age for
tissue collection.
RESULTS—Before diabetes onset energy intake, body weight,
adiposity, and liver triglyceride content were higher in control
animals compared with restricted and liraglutide-treated rats.
Energy-restricted animals had lower food intake than liraglutide-
treated animals to maintain the same body weights, suggesting
that liraglutide increases energy expenditure. Liraglutide treat-
ment delayed diabetes onset by 4.1  0.8 months compared with
control (P  0.0001) and by 1.3  0.8 months compared with
restricted animals (P  0.05). Up to 6 months of age, energy
restriction and liraglutide treatment lowered fasting plasma
glucose and A1C concentrations compared with control animals.
In contrast, liraglutide-treated animals exhibited lower fasting
plasma insulin, glucagon, and triglycerides compared with both
control and restricted animals. Furthermore, energy-restricted
and liraglutide-treated animals exhibited more normal islet
morphology.
CONCLUSIONS—Liraglutide treatment delays the development
of diabetes in UCD-T2DM rats by reducing energy intake and
body weight, and by improving insulin sensitivity, improving lipid
proﬁles, and maintaining islet morphology. Diabetes 59:2653–
2661, 2010
T
argeting of glucagon-like peptide-1 (GLP-1) for
the pharmaceutical treatment of type 2 diabetes
has shown much promise, as demonstrated by
the clinical success of GLP-1 agonists and dipep-
tidyl peptidase IV (DPP-IV) inhibitors (1,2). As an incretin
hormone, GLP-1 potentiates glucose-induced insulin se-
cretion, avoiding hypoglycemia observed with other phar-
maceutical activators of insulin secretion such as
sulfonylureas (3,4). GLP-1 has also been shown to reduce
excess glucagon secretion, contributing to a reduction in
hyperglycemia (1), and has been suggested to reduce
inﬂammation (5). GLP-1 signaling increases satiety (6,7)
and slows gastric motility and secretion, further contrib-
uting to a reduction in food intake (8). Furthermore, GLP-1
has been shown to increase -cell differentiation, prolifer-
ation, and insulin synthesis and decrease -cell apoptosis
(9–11). Finally, administration of GLP-1 can improve insu-
lin sensitivity by promoting peripheral glucose uptake and
decreasing hepatic gluconeogenesis, independent of
changes of pancreatic hormone secretion (12–16).
Early attempts to harness these antidiabetic effects
through the production of GLP-1 analogs were complicated
by the short half-life of endogenous GLP-1 (2 min) because
of rapid degradation by the ubiquitously expressed protease,
DPP-IV (17). Thus, one method currently being pursued for
the therapeutic targeting of GLP-1 is production of GLP-1
analogs that are resistant to degradation by DPP-IV. Lira-
glutide is a GLP-1 analog with an additional 16-carbon fatty
acid and a small amino acid–based spacer that confers
reversible binding of the agonist to albumin and increases
resistance to DPP-IV activity, providing liraglutide with a
half-life of approximately 13 h (18,19). These properties allow
once-daily subcutaneous administration of liraglutide for the
treatment of type 2 diabetes.
The efﬁcacy of liraglutide for the treatment of type 2
diabetes has been demonstrated in a number of clinical
studies, with patients showing signiﬁcant decreases in body
weight, glucose, A1C, and blood pressure (20–25). However,
preclinical studies of the long-term use of chronic liraglutide
administration for the prevention of type 2 diabetes have not
been conducted. With the increasing prevalence of type 2
diabetes, preventive measures are urgently needed. Thus,
this study investigated the metabolic effects of chronic lira-
glutide administration and the potential of liraglutide to
prevent or delay the development of type 2 diabetes in
pre-diabetic UCD-T2DM rats. The UCD-T2DM rat model
develops polygenic adult-onset obesity and insulin resis-
tance, without a monogenic deﬁcit in leptin signaling, fol-
From the
1Department of Molecular Biosciences, School of Veterinary Medi-
cine, University of California, Davis, Davis, California; the
2Department of
Nutrition, University of California, Davis, Davis, California; the
3Research
and Development Service, Department of Veterans Affairs Puget Sound
Health Care System, Seattle, Washington, and the Department of Medicine,
Division of Metabolism, Endocrinology, and Nutrition, University of
Washington, Seattle, Washington; the
4Department of Internal Medicine,
University of California, Davis, Sacramento, California;
5Biology and
Pharmacology Management, Novo Nordisk, Maaloev, Denmark; and the
6Diabetes Inﬂammation Department, Novo Nordisk, Gentofte, Denmark.
Corresponding author: Peter J. Havel, pjhavel@ucdavis.edu.
Received 22 October 2009 and accepted 30 June 2010. Published ahead of
print at http://diabetes.diabetesjournals.org on 9 July 2010. DOI:
10.2337/db09-1564.
© 2010 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
ORIGINAL ARTICLE
diabetes.diabetesjournals.org DIABETES, VOL. 59, OCTOBER 2010 2653lowed by inadequate -cell compensation and diabetes in
both male and female animals (26). Thus, the UCD-T2DM rat
more closely models the pathogenesis of type 2 diabetes in
humans than other currently available models. Furthermore,
UCD-T2DM rats demonstrate a later age of diabetes onset
than other rodent models of type 2 diabetes, such as the ZDF
rat, making them highly suitable for diabetes prevention
studies (26,27).
RESEARCH DESIGN AND METHODS
Male UCD-T2DM rats from our colony were individually housed in hanging
wire cages in the Department of Nutrition animal facility at the University of
California, Davis, and maintained on a 1410 h light-dark cycle. Starting when
rats were 2 months of age, male siblings were divided into three groups:
control, food restricted, and liraglutide. Animals with a 2-month body weight
375 g were chosen for the study. Previous data from our laboratory have
shown that animals weighing 375 g at 2 months of age have an average age
of diabetes onset of 113  5 days and a diabetes incidence rate of 98%,
whereas animals weighing 375 g at 2 months of age have an average age of
onset of 219  10 days and a diabetes incidence rate of 89% (26). Body weights
at the time of entry into the study were 398  3, 399  3, and 399  3gi n
control, food-restricted, and liraglutide groups, respectively (n  32 per
group). All animals received ground chow (no. 5012, Ralston Purina, Belmont,
CA) in spill-resistant jars for accurate food intake measurements. Restricted
animals were food restricted to 9% less energy per kg of body weight than was
being consumed by the liraglutide-treated animal in the same cohort to
equalize body weights between these two groups. Food intake and body
weight were measured three times weekly. Control and food-restricted
animals received subcutaneous Dulbecco’s PBS injections (1 ml/kg body
weight) twice daily (0800–1000 h and 1800–2000 h), and liraglutide animals
received subcutaneous liraglutide injections (0.2 mg/kg body weight) twice
daily. Animals received injections after the fasting blood draws and did not
receive an injection on the day of euthanasia. Nonfasting blood glucose was
monitored every week with a glucose meter (LifeScan One-Touch Ultra,
Milpitas, CA) at 1300–1400 h using a lancet to collect a drop of blood from the
tail. Diabetes onset was deﬁned as a nonfasted blood glucose value above 11.1
mmol/l (200 mg/dl) on 2 consecutive weeks. Half of the animals in each group
(n  16) were killed for tissue collection at 6.5 months of age (short-term
study). The remaining half (n  16) continued treatment until the time of
diabetes onset (long-term study). The experimental protocols were approved
by the UC Davis Institutional Animal Care and Use Committee.
Monthly hormone and metabolic proﬁles. Blood samples were collected
from rats in both the short-term and long-term treatment groups once monthly
after an overnight (13-h) fast and placed into EDTA-treated tubes. The plasma
was separated by centrifugation and assayed for glucose, insulin, glucagon,
triglycerides (TG), cholesterol, and adiponectin. Plasma monocyte chemotac-
tic protein-1 (MCP-1) was measured in plasma samples from 6-month-old rats.
Plasma leptin and intercellular adhesion molecule (I-CAM) were measured in
the ﬁnal blood sample taken from 6.5-month-old rats from the short-term
group. Twenty-four–hour urine samples were collected from 6-month-old rats
in the short-term groups in sodium azide–treated ﬂasks and assayed for
glucose and albumin.
Plasma glucose, cholesterol, and urine glucose were measured using
enzymatic colorimetric assays for glucose and cholesterol (Thermo DMA
Louisville, CO). Insulin, leptin, glucagon, and adiponectin were measured with
rodent/rat-speciﬁc radioimmunoassays (Millipore, St. Charles, MO). TG was
measured with an enzymatic colorimetric assay (L-type TG H kit, Wako
Chemicals, Richmond, VA). Plasma I-CAM was measured when the rats were
6 months of age with an ELISA (R&D, Minneapolis, MN). Plasma monocyte
chemotactic protein-1 (MCP-1) levels were compared in 5 diluted plasma
from 6-month-old rats using the Millipore Milliplex assay (RAT cytokine cat.
no. RCYTO-80K). Urinary albumin excretion was measured using the Albumin
Blue 580 ﬂuorescence assay method described previously (28). A1C was
measured using the direct enzymatic HbA1c kit (Diazyme, Poway, CA).
Body composition and liver and muscle triglyceride content. After 4.5
months of treatment (6.5 months of age), animals in the short-term groups
were killed with an overdose of pentobarbital (200 mg/kg i.p.) after an
overnight fast. Subcutaneous, mesenteric, retroperitoneal, and epididymal
adipose depots and liver, heart, gastrocnemius muscle, and kidney were
dissected, weighed, and ﬂash-frozen in liquid nitrogen and stored at 80°C.
Liver and skeletal muscle TG content were measured using the Folch method
(29) for lipid extraction followed by spectrophotometric measurement of TG
content (Thermo Electron, Louisville, CO). Rats were eviscerated and fat
depots were returned to the carcass for body composition analysis, conducted
as described by Bell and Stern (30). Brieﬂy, carcass weight was determined,
and the carcass was freeze-dried to determine total water weight, placed in a
soxhlet ether extractor to determine total fat weight, and then placed in a
mufﬂe oven to determine total ash weight.
Islet immunohistochemistry and pancreatic insulin content. Pancreas
samples were collected and immunostained, and insulin was extracted and
analyzed as previously described (31).
Statistics and data analysis. Data are presented as mean  SEM. Statistical
analyses were performed using GraphPad Prism 4.00 for Windows, GraphPad
Software, San Diego, CA. Body weight, food intake, and monthly fasting
hormone and metabolite data were compared by two-factor (time and
treatment) repeated-measures ANOVA followed by post hoc analysis with a
Bonferroni multiple comparison test. Incidence data were analyzed by log-
rank testing of Kaplan-Meier survival curves. Age of onset, tissue weights,
tissue TG content, plasma leptin, plasma I-CAM, plasma MCP-1, and body
composition were analyzed by one-factor ANOVA followed by post hoc
analysis with Bonferroni multiple comparison test. Differences were consid-
ered signiﬁcant at P  0.05. For tissue weights and body composition data,
animals that had become diabetic and had started to lose weight (at least 5%
of peak weight) were not included in this dataset to avoid the confounding
effects of weight loss on tissue TG content and adiposity. Five animals from
the control group and one from the restricted group became diabetic at too
early an age to allow collection of blood samples up to 6 months of age, and
therefore they were included in incidence analysis, but excluded from
longitudinal analyses.
RESULTS
Chronic liraglutide administration delays the onset
of diabetes. Compared with control animals, the onset of
diabetes was delayed in food-restricted and liraglutide-
treated animals by 2.8  0.7 and 4.1  0.8 months of age,
respectively. The mean ages of diabetes onset were 5.2 
0.6, 8.0  0.7, and 9.3  0.8 months in control, food-
restricted, and liraglutide-treated animals, respectively
(Table 1). By 6.5 months of age, only 5 of 32 liraglutide-
TABLE 1
Age of onset and incidence
Control Restricted Liraglutide-treated
Animals treated until 6.5 months of age
Age of onset (days) 127  6 160  6** 163  12*
Incidence (%) 81 38 16
Diabetes-free days 79  7 122  4*** 130  3***
n 32 32 32
Animals treated until onset
Age of onset (days) 156  18 240  22* 280  25**
Incidence (%) 100 100 100
Diabetes-free days† 96  18 179  21* 207  19***
n 16 16 16
Data are mean  SEM unless otherwise indicated. P  0.01 by one-way ANOVA; *P  0.05; **P  0.01; ***P  0.001 compared with control
by Bonferroni post-test. †Diabetes-free days starting at treatment initiation.
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food-restricted and 26 of 32 control animals were diabetic.
Thus, within the ﬁrst 4 months of treatment, liraglutide
treatment signiﬁcantly delayed diabetes onset compared
with both the control and food-restricted groups (Fig. 1A).
After 15 months of treatment, liraglutide and food restric-
tion both signiﬁcantly delayed diabetes onset compared with
control animals (P  0.01), but at this lower sample size and
longer time course of treatment, the time of onset was not
signiﬁcantly different between food-restricted and liraglutide
long-term treatment groups (Fig. 1B). Nonfasting blood glu-
cose concentrations were signiﬁcantly elevated in control
animals compared with restricted and liraglutide-treated
animals starting at 4 months of age (Fig. 1C).
Liraglutide treatment reduces energy intake and
body weight. As expected, energy intake and body weight
were signiﬁcantly higher in control animals compared with
restricted and liraglutide-treated animals throughout the
study (Fig. 2). Energy intake was maintained 9% lower in
restricted animals compared with liraglutide-treated ani-
mals to equalize body weights between these groups.
Control animals began to lose weight at 6 months of age as
the majority of these untreated animals had developed
diabetes and were losing energy because of glucosuria and
polyuria (Table 2). Diabetic animals developed moderate
hyperphagia as previously reported, likely because of
decreases of insulin and leptin (26).
Liraglutide lowers fasting glucose, A1C, insulin, and
urinary albumin excretion. Fasting plasma glucose and
A1C were elevated in control animals compared with
food-restricted and liraglutide-treated animals, reﬂecting
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FIG. 1. Kaplan-Meier analysis of diabetes incidence in control, re-
stricted, and liraglutide-treated animals up to 6 months (n  32 per
group) (A) and 12 months (n  16 per group) (B) of age. ***P < 0.0001,
**P < 0.01 compared with control; *P < 0.05 compared with the
food-restricted group by log-rank test. Nonfasting blood glucose in
control, restricted, and liraglutide-treated animals (C). ***P < 0.0001
by two-factor (time and treatment) repeated-measures ANOVA, ***P <
0.001 compared with restricted and liraglutide-treated animals by
Bonferroni post-test. Control: n  27; restricted: n  31; liraglutide-
treated animals: n  32.
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FIG. 2. Energy intake (A) and body weight (B) in control, restricted,
and liraglutide-treated animals. ***P < 0.0001 by two-factor (time and
treatment) repeated-measures ANOVA; ***P < 0.001 compared with
restricted and liraglutide-treated animals; *P < 0.05 liraglutide-
treated animals versus restricted by Bonferroni post-test. Control: n 
27; restricted: n  31; liraglutide-treated animals: n  32.
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Similar to urine glucose values, daily urine albumin excre-
tion in 6-month-old rats was signiﬁcantly higher in control
animals compared with food-restricted and liraglutide-
treated animals (Table 2).
Liraglutide treatment markedly lowered fasted plasma
insulin compared with control and food-restricted animals
starting 1 month into intervention and lasting throughout
the 6-month sampling period, suggesting that the improved
insulin sensitivity was not solely related to reduced body
weight (Fig. 3C)( P  0.001). Fasting insulin concentra-
tions in the control group began to fall starting at 5 months
of age as more of these animals developed diabetes. We
previously reported that fasting plasma insulin concentra-
tions decline progressively with the duration of diabetes in
the UCD-T2DM rat model as a result of -cell failure (26).
Liraglutide decreases body adiposity. In animals killed
at 6.5 months of age, food-restricted and liraglutide-treated
animals weighed signiﬁcantly less than control animals
and had smaller epididymal and mesenteric adipose de-
pots (Table 3) (P  0.01). Although food restriction
resulted in a decrease of percent body fat content and an
increase of the percent lean body mass compared with
nondiabetic controls, liraglutide treatment further de-
creased percentage body fat and increased lean body mass
compared with food-restricted animals (Table 3). Lira-
glutide-treated animals also had 15% lower heart weights
and higher percentage body mineral (bone ash) content
compared with control animals.
Liraglutide lowers fasting TG and liver TG content.
Fasting plasma TG concentrations were reduced 50–60%
in liraglutide-treated animals compared with control and
food-restricted animals throughout the 6-month sampling
period (Fig. 4A). Liver TG content was signiﬁcantly lower
in both food-restricted and liraglutide-treated animals at
6.5 months of age compared with control animals (Table
3). No signiﬁcant differences in muscle TG content or
plasma cholesterol were observed (Fig. 4B).
Liraglutide lowers plasma glucagon and leptin, main-
tains plasma adiponectin, and does not affect mark-
ers of inﬂammation. When the rats were 3 months of
age, fasting plasma glucagon concentrations were signiﬁ-
cantly lower in liraglutide-treated animals compared with
food-restricted and control animals (Fig. 4C). Fasting
plasma leptin was signiﬁcantly lower in liraglutide-treated
animals compared with food-restricted and control ani-
mals at 6.5 months of age, after exclusion of animals that
had become diabetic and had started to lose weight
(control: 1,034  168; restricted: 1,031  344; liraglutide:
730  237 pmol/l; P  0.05; control: n  6; restricted: n 
14; liraglutide: n  14). Plasma adiponectin concentrations
were maintained in restricted and liraglutide animals up to
6 months of age, whereas plasma adiponectin levels fell by
33  12 pmol/l (P  0.05) in 4-month-old rats compared
with baseline concentrations in the control animals (Fig.
4D). Liraglutide treatment did not lower fasting plasma
I-CAM concentrations in 6.5-month-old pre-diabetic ani-
mals compared with control animals; however, food re-
striction signiﬁcantly lowered I-CAM concentrations
(control: 286.2  54.4; restricted: 202.1  6.1, liraglutide:
355.9  75.1 nmol/l; P  0.05, control compared with
restricted; control: n  6; restricted: n  14; liraglutide:
n  14). Plasma MCP-1 concentrations were lower in
restricted and liraglutide-treated animals compared with
control animals at 6 months of age (control: 3.0  0.5;
restricted: 1.8  0.2; liraglutide: 2.0  0.3 pmol/l; control:
n  29; restricted: n  27; liraglutide: n  29). However,
plasma MCP-1 concentrations were not different between
groups when diabetic animals were excluded (control:
2.2  0.5; restricted: 1.8  0.2; liraglutide: 2.0  0.3 pmol/l;
control: n  11; restricted: n  23; liraglutide: n  27).
Liraglutide and energy restriction improve islet mor-
phology and increase pancreatic insulin content. Im-
munostaining for insulin and glucagon was performed
on a subset of nine animals per group to assess islet
morphology. Figure 5 presents representative images of
islets from control, food-restricted, and liraglutide-
treated animals. Insulin staining appeared greater in
islets from food-restricted and liraglutide-treated ani-
mals compared with control animals. This was expected
since 8 of the 9 control animals had developed diabetes
at the time of kill, whereas only 3 of 9 and 2 of 9 animals
selected for immunostaining were diabetic prior to kill
in the food-restricted and liraglutide-treated groups,
respectively. Animals in the control group had been
diabetic for 64  13 days, whereas animals in the
liraglutide and restricted groups had only been diabetic
for 38  3 and 26  11 days, respectively. There were no
visible differences noted between the islets from the one
nondiabetic control animal and those from the nondia-
betic restricted and liraglutide animals (data not
shown). No signiﬁcant visible differences in islet mor-
phology were apparent between food-restricted and
liraglutide-treated animals (Fig. 5). Pancreatic insulin
content in the control animals was approximately one-
third of that of food-restricted and liraglutide-treated
animals (Table 3).
DISCUSSION
In the present study, we investigated the favorable meta-
bolic effects of liraglutide administration (0.2 mg/kg body
weight) and the potential of liraglutide to prevent the
development of diabetes in pre-diabetic UCD-T2DM rats.
Previous studies of liraglutide in rodents and humans have
demonstrated reductions of food intake and body weight,
TABLE 2
Urine volume (24-h), urine glucose, and albumin concentrations and excretion in 6-month-old rats
Control Restricted Liraglutide-treated
Urine glucose (mmol/l) 294  40 59  33*** 78  41***
24-h urine volume (ml) 112  19 15  3*** 29  9***
24-h urine glucose output (mg) 7,201  1,473 374  273*** 1,337  823***
Urinary albumin excretion (mg/day) 14.6  4.8 0.6  0.1** 0.9  0.2**
n 16 15 16
Data are means  SEM unless otherwise indicated. P  0.001 by one-way ANOVA; **P  0.01, ***P  0.001 compared with control by
Bonferroni post-test.
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centrations, and subsequent improvements of insulin sen-
sitivity and plasma glucose (20–25,32,33). In this study, we
report that chronic liraglutide administration substantially
delays the onset of diabetes as assessed by reductions of
circulating glucose and A1C in UCD-T2DM rats compared
with vehicle-treated control animals, and it modestly de-
lays diabetes onset compared with food-restricted animals
matched for body weight.
The large effects of energy restriction alone to delay the
onset of diabetes in this study suggest that a substantial
portion of the effects of chronic liraglutide administration
on diabetes onset are a result of its effect to reduce food
intake and body weight. Reductions of energy intake and
body weight resulting from liraglutide administration are
similar to that reported in other rodent studies (32,33).
Food restriction is well known to lower glucose, A1C, and
requirements for insulin (34); however, long-term compli-
ance with voluntary food restriction regimens is rarely
achieved. Treatment with liraglutide, a long-acting GLP-1
analog, has the beneﬁt of achieving such reductions in
food intake and body weight.
Although energy restriction played a key role in the
effect of liraglutide to delay type 2 diabetes onset, differ-
ences between liraglutide-treated and food-restricted ani-
mals suggest additional antidiabetic actions of liraglutide
treatment. First, similar body weights in the liraglutide and
restricted groups, despite signiﬁcantly lower food intake
in the restricted group, suggests that liraglutide treatment
increases energy expenditure. This has been previously
suggested by the results of a study in which a 10% increase
of energy expenditure was observed in rats treated with
liraglutide (33). Furthermore, lower percentage of body fat
mass in liraglutide-treated compared with food-restricted
animals, despite similar body weight, is suggestive of a
preferential increase of lipid oxidation with liraglutide
treatment compared with energy restriction alone.
Second, substantially lower fasting plasma insulin con-
centrations in liraglutide-treated animals compared with
food-restricted animals, despite similar plasma glucose
concentrations, suggest that liraglutide administration im-
proves insulin sensitivity, independent of effects on food
intake and body weight. The mechanisms by which GLP-1
signaling improves insulin sensitivity remain incompletely
understood. There is increasing evidence that GLP-1 may act
to enhance peripheral insulin sensitivity and reduce hepatic
gluconeogenesis independent of its effects on pancreatic
hormones (35), which may be mediated by portal GLP-1
receptors that signal to the CNS through vagal afferent nerves
and autonomic efferent signals to insulin target tissues such
as adipose, liver, and muscle (36).
This improvement in insulin sensitivity may have con-
tributed to the lower circulating TG concentrations in
liraglutide-treated compared with both control and food-
restricted animals. Liver TG content was also signiﬁcantly
lower in liraglutide-treated and food-restricted animals.
Reductions of circulating and ectopic TG content are
likely to contribute to the improvement in insulin sensitiv-
ity, as deposition of TG in the liver impairs insulin signal-
ing through the production of lipid metabolites that reduce
insulin receptor substrate-2 tyrosine phosphorylation (37).
Additional studies are needed to investigate the mecha-
nisms involved in the effects of liraglutide to lower circu-
lating TG and to determine the extent to which this
contributes to the liraglutide-induced improvement of
insulin sensitivity and delay of diabetes onset.
Lower glucagon levels during the ﬁrst 2 months of
treatment in liraglutide-treated animals may have contrib-
uted to lower glucose levels, as glucagon promotes hepatic
gluconeogenesis and the production of gluconeogenic
substrates from other energy stores (38). This GLP-1–
mediated improvement of 	-cell function is in agreement
with previous studies (1), and it is consistent with in-
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FIG. 3. Fasting circulating glucose (A), A1C (B), and insulin (C)i n
control, restricted, and liraglutide-treated animals. ***P < 0.0001 by
two-factor (time and treatment) repeated-measures ANOVA; ***P <
0.001, *P < 0.05 compared with restricted and liraglutide-treated
animals; **P < 0.001 compared with restricted and control;
P <
0.001 compared with restricted;
P < 0.05 compared with control by
Bonferroni post-test. Control: n  27; restricted: n  31; liraglutide-
treated animals: n  32.
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receptor knockout mouse (39).
The lower plasma leptin concentrations in liraglutide-
treated animals are likely the result of the decreased
insulin levels observed in response to chronic liraglutide
administration, as leptin production is regulated by insu-
TABLE 3
Body composition, tissue TG content, and pancreatic insulin content in 6.5-month-old rats
Control Restricted Liraglutide-treated
Body weight (g) 647  16 574  7*** 573  11***
Epididymal fat depots (g) 12.0  0.4 9.3  0.4** 8.5  0.5***
Retroperitoneal fat depots (g) 13.7  0.3 12.5  0.7 11.1  0.7
Subcutaneous fat depot (g) 61  35 1  34 6  2*
Mesenteric fat depot (g) 11.1  0.5 8.2  0.4** 8.0  0.6**
Total white adipose tissue (g) 98  48 1  57 4  4**
Heart (g) 1.7  0.1 1.5  0.1 1.4  0.1*
Kidney (g) 1.8  0.1 1.7  0.1 1.8  0.1
Liver (g) 21.3  0.9 17.4  0.5*** 17.1  0.4***
Liver TG (mg/g liver) 23.0  1.4 13.3  1.7*** 13.2  1.1**
Skeletal muscle TG (mg/g muscle) 3.3  0.4 4.2  0.6 3.2  0.3
Pancreatic insulin content (
g/g) 7  32 1  3* 25  5**
% Body fat 23.9  0.8 22.6  0.9 20.0  0.9*†
% Lean body mass 21.3  0.1 21.4  0.2 22.1  0.2*†
% Body water 51.2  0.7 52.2  0.8 53.9  0.7
% Body ash 3.6  0.1 3.8  0.1 3.9  0.1**
Data are means  SEM. Control: n  6; restricted: n  14; liraglutide-treated: n  14. For pancreatic insulin content, control: n  10;
restricted: n  9; liraglutide-treated: n  10. One-way ANOVA; *P  0.05; **P  0.01; ***P  0.001 compared with control; †P  0.05
compared with restricted. Data exclude all animals that became diabetic and began losing weight.
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FIG. 4. Fasting plasma TG (A), cholesterol (B), glucagon (C), and adiponectin (D) in control, food-restricted, and liraglutide-treated animals.
***P < 0.0001, *P < 0.05 by two-factor (time and treatment) repeated-measures ANOVA; ***P < 0.001 compared with food-restricted and control;
**P < 0.001 compared with food-restricted; *P < 0.05 compared with control;
P < 0.05 compared with food-restricted;
P < 0.05 compared with
food-restricted and liraglutide-treated animals by Bonferroni post-test. Control: n  27; restricted: n  31; liraglutide-treated animals: n  32.
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adiposity in liraglutide-treated rats may also have contrib-
uted to lower leptin concentrations (41). Lower heart
weights in liraglutide-treated animals compared with con-
trol animals appear consistent with the beneﬁcial effects
that GLP-1 signaling has been reported to have on cardiac
function (1). Liraglutide did not have a signiﬁcant effect on
markers of inﬂammation in pre-diabetic rats; thus, the
delay in diabetes onset does not appear to be inﬂuenced by
inﬂammatory status.
Several parameters were similar between the food-
restricted and liraglutide-treated groups, further indicating
the importance of energy restriction and reduced adiposity
in delaying the onset of diabetes in the UCD-T2DM rat
model. Circulating levels of the insulin-sensitizing adipo-
cyte hormone adiponectin (41) were elevated in both
liraglutide-treated and food-restricted animals compared
with control animals starting at 4 months of age. This is
reﬂective of the later age of diabetes onset in these two
treatment groups, as we have previously reported that
adiponectin levels fall after the onset of diabetes in
UCD-T2DM rats, potentially contributing to the progres-
sion of type 2 diabetes (26). Higher circulating adi-
ponectin concentrations may also have contributed to
the lower glucose levels in both the liraglutide-treated
and food-restricted groups by maintaining insulin
sensitivity.
Liraglutide treatment and energy restriction equally
preserved islet morphology and pancreatic insulin con-
tent. Both treatments delayed the onset of diabetes such
that none of the restricted or liraglutide animals had been
diabetic for 1.5 months prior to tissue collection at 6.5
months of age. The deterioration of islet morphology and
insulin staining during the progression of diabetes has
been previously documented in the UCD-T2DM rat model
(26), and it is clearly demonstrated in the control animals
that had diabetes for 1 month. These observations are
also consistent with those reported in pancreata from
humans with type 2 diabetes (42). Thus, the preservation
of islet morphology and pancreatic insulin content during
food restriction or liraglutide administration in UCD-
T2DM rats may be a result of slower weight gain and a
consequent delay in the onset of hyperglycemia and pos-
sibly glucose toxicity. The effects of liraglutide administra-
tion and food restriction to delay the onset of diabetes and
reduce hyperglycemia were also associated with markedly
reduced urinary albumin excretion, indicating that delay-
ing diabetes onset in UCD-T2DM rats delays the develop-
ment of diabetic complications such as nephropathy.
In conclusion, both liraglutide treatment and energy
D
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C
FIG. 5. Representative pancreas sections from control, food-restricted, and liraglutide-treated animals at 6 months of age. Hematoxylin and eosin
staining for control (A), restricted (D), and liraglutide-treated animals (G) is shown. Anti-insulin immunostaining for control (B), restricted (E),
and liraglutide-treated animals (H) is shown. Anti-glucagon immunostaining for control (C), restricted (F), and liraglutide-treated animals (I)
is shown. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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rats by slowing weight gain, obesity-associated insulin
resistance, and islet dysfunction. Sustained liraglutide
administration delayed the onset of diabetes compared
with food-restricted, body weight–matched animals. This
delay may be the result of improved insulin sensitivity and
decreased circulating TG and glucagon concentrations
seen with liraglutide administration relative to energy
restriction alone. Thus, chronic liraglutide treatment is an
effective weight management tool that delays the onset of
type 2 diabetes. This is the ﬁrst preclinical study investi-
gating the long-term use of chronic liraglutide administra-
tion for the prevention of type 2 diabetes. Determining
preventive indications for currently available and develop-
ing therapies is crucial in the attempt to reduce the
growing worldwide burden of type 2 diabetes. Delaying
the onset of type 2 diabetes and reducing hyperglycemia in
predisposed individuals would have multiple beneﬁts, in-
cluding delaying the onset of diabetic complications, im-
proving patient quality of life, and reducing health care
expenses.
ACKNOWLEDGMENTS
This research was supported by Novo Nordisk, Bags-
værd, Denmark. P.J.H.’s laboratory also receives or has
received funding during the project period from the
National Institutes of Health grants R01-HL075675, R01-
HL09333, AT0-02599, AT0-02993, and AT0-03545. Immuno-
histochemistry and islet analysis work was supported by
the National Institutes of Health Grant P30 DK-17047
through the Cellular and Molecular Imaging Core of the
University of Washington Diabetes Endocrinology Re-
search Center.
The immunohistochemistry studies were supported by
the facilities at the Veterans Affairs Puget Sound Health
Care System, Seattle, Washington. D.G.B. is Senior Re-
search Career Scientist, Research and Development Ser-
vice, Department of Veterans Affairs Puget Sound Health
Care System, Seattle, Washington.
C.N., A.S., L.B.K., and K.R. are full-time employees of
Novo Nordisk and are also minor stock owners as part of
an employee offering program. Novo Nordisk markets
liraglutide for treatment of type 2 diabetes. S.C.G. is
currently employed by Bristol-Myers Squibb. P.J.H.’s lab-
oratory received funding from Novo Nordisk to perform
this project.
No other potential conﬂicts of interest relevant to this
article were reported.
B.P.C. developed and characterized the UCD-T2DM rat
model used for the study, designed and obtained funding
for the study, conducted the experiments, analyzed data,
wrote the manuscript, and edited the manuscript for
intellectual content. K.L.S. developed and characterized
the UCD-T2DM rat model used for the study, designed and
obtained funding for the study, conducted the experi-
ments, analyzed data, wrote the manuscript, edited the
manuscript for intellectual content, and had primary re-
sponsibility for ﬁnal content. J.L.G. developed and charac-
terized the UCD-T2DM rat model used for the study,
designed and obtained funding for the study, conducted
the experiments, analyzed data, and edited the manuscript
for intellectual content. D.G.B. analyzed data and edited
the manuscript for intellectual content. S.C.G. developed
and characterized the UCD-T2DM rat model used for the
study and edited the manuscript for intellectual content.
C.N. edited the manuscript for intellectual content. A.S.
conducted the experiments, analyzed data, and edited the
manuscript for intellectual content. L.B.K. and K.R. de-
signed and obtained funding for the study and edited the
manuscript for intellectual content. P.J.H. developed and
characterized the UCD-T2DM rat model used for the study,
designed and obtained funding for the study, analyzed
data, edited the manuscript for intellectual content, and
had primary responsibility for ﬁnal content.
Parts of this study were presented in abstract form at
the 69th Scientiﬁc Sessions of the American Diabetes
Association, New Orleans, Louisiana, 5–9 June 2009.
The authors thank Sunhye Kim for extensive help with
animal care, monitoring, and data collection; Joyce Mur-
phy for excellent technical support with pancreatic immu-
nohistochemistry; Noreene Shibata for body composition
analysis; and Riva Dill for animal care assistance.
REFERENCES
1. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenter-
ology 2007;132:2131–2157
2. Herman GA, Stein PP, Thornberry NA, Wagner JA. Dipeptidyl peptidase-4
inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Clin
Pharmacol Ther 2007;81:761–767
3. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1
7–36: a physiological incretin in man. Lancet 1987;2:1300–1304
4. Mojsov S, Weir GC, Habener JF. Insulinotropin: glucagon-like peptide I
(7-37) co-encoded in the glucagon gene is a potent stimulator of insulin
release in the perfused rat pancreas. J Clin Invest 1987;79:616–619
5. Kim Chung le T, Hosaka T, Yoshida M, Harada N, Sakaue H, Sakai T,
Nakaya Y. Exendin-4, a GLP-1 receptor agonist, directly induces adiponec-
tin expression through protein kinase A pathway and prevents inﬂamma-
tory adipokine expression. Biochem Biophys Res Commun 2009;390:613–
618
6. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes
satiety and suppresses energy intake in humans. J Clin Invest 1998;101:
515–520
7. Gutzwiller JP, Drewe J, Goke B, Schmidt H, Rohrer B, Lareida J, Beglinger
C. Glucagon-like peptide-1 promotes satiety and reduces food intake in
patients with diabetes mellitus type 2. Am J Physiol 1999;276:R1541–R1544
8. Wren AM, Bloom SR. Gut hormones and appetite control. Gastroenterol-
ogy 2007;132:2116–2130
9. D’Alessio DA, Vahl TP. Glucagon-like peptide 1: evolution of an incretin
into a treatment for diabetes. Am J Physiol Endocrinol Metab 2004;286:
E882–E890
10. Merani S, Truong W, Emamaullee JA, Toso C, Knudsen LB, Shapiro AM.
Liraglutide, a long-acting human glucagon-like peptide 1 analog, improves
glucose homeostasis in marginal mass islet transplantation in mice.
Endocrinology 2008;149:4322–4328
11. Salehi M, Aulinger BA, D’Alessio DA. Targeting beta-cell mass in type 2
diabetes: promise and limitations of new drugs based on incretins. Endocr
Rev 2008;29:367–379
12. D’Alessio DA, Kahn SE, Leusner CR, Ensinck JW. Glucagon-like peptide 1
enhances glucose tolerance both by stimulation of insulin release and by
increasing insulin-independent glucose disposal. J Clin Invest 1994;93:
2263–2266
13. Gedulin BR, Nikoulina SE, Smith PA, Gedulin G, Nielsen LL, Baron AD,
Parkes DG, Young AA. Exenatide (exendin-4) improves insulin sensitivity
and -cell mass in insulin-resistant obese fa/fa Zucker rats independent of
glycemia and body weight. Endocrinology 2005;146:2069–2076
14. Gonzalez N, Acitores A, Sancho V, Valverde I, Villanueva-Penacarrillo ML.
Effect of GLP-1 on glucose transport and its cell signalling in human
myocytes. Regul Pept 2005;126:203–211
15. Prigeon RL, Quddusi S, Paty B, D’Alessio DA. Suppression of glucose
production by GLP-1 independent of islet hormones: a novel extrapancre-
atic effect. Am J Physiol Endocrinol Metab 2003;285:E701–E707
16. Redondo A, Trigo MV, Acitores A, Valverde I, Villanueva-Penacarrillo ML.
Cell signalling of the GLP-1 action in rat liver. Mol Cell Endocrinol
2003;204:43–50
17. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1
by human plasma in vitro yields an N-terminally truncated peptide that is
a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995;80:
952–957
LIRAGLUTIDE DELAYS TYPE 2 DIABETES ONSET
2660 DIABETES, VOL. 59, OCTOBER 2010 diabetes.diabetesjournals.org18. Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M. The pharmaco-
kinetics, pharmacodynamics, safety and tolerability of NN2211, a new
long-acting GLP-1 derivative, in healthy men. Diabetologia 2002;45:195–202
19. Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen
FZ, Thogersen H, Wilken M, Agerso H. Potent derivatives of glucagon-like
peptide-1 with pharmacokinetic properties suitable for once daily admin-
istration. J Med Chem 2000;43:1664–1669
20. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH,
Zychma M, Blonde L. Liraglutide once a day versus exenatide twice a day
for type 2 diabetes: a 26-week randomised, parallel-group, multinational,
open-label trial (LEAD-6). Lancet 2009;374:39–47
21. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H,
Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B. Liraglutide versus
glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a random-
ised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet
2009;373:473–481
22. Marre M, Shaw J, Brandle M, Bebakar WM, Kamaruddin NA, Strand J,
Zdravkovic M, Le Thi TD, Colagiuri S. Liraglutide, a once-daily human
GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater
improvements in glycaemic and weight control compared with adding
rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU).
Diabet Med 2009;26:268–278
23. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic
M, During M, Matthews DR. Efﬁcacy and safety comparison of liraglutide,
glimepiride, and placebo, all in combination with metformin, in type 2
diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Diabetes Care 2009;32:84–90
24. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic
M, Ravn GM, Simo R. Liraglutide vs insulin glargine and placebo in
combination with metformin and sulfonylurea therapy in type 2 diabetes
mellitus (LEAD-5 metSU): a randomised controlled trial. Diabetologia
2009;52:2046–2055
25. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM,
Zdravkovic M, Blonde L. Efﬁcacy and safety of the human glucagon-like
peptide-1 analog liraglutide in combination with metformin and thiazo-
lidinedione in patients with type 2 diabetes (LEAD-4 MetTZD). Diabetes
Care 2009;32:1224–1230
26. Cummings BP, Digitale EK, Stanhope KL, Graham JL, Baskin DG, Reed BJ,
Sweet IR, Griffen SC, Havel PJ. Development and characterization of a
novel rat model of type 2 diabetes mellitus: the UC Davis type 2 diabetes
mellitus UCD-T2DM rat. Am J Physiol Regul Integr Comp Physiol 2008;
295:R1782–R1793
27. Bergeron R, Yao J, Woods JW, Zycband EI, Liu C, Li Z, Adams A, Berger JP,
Zhang BB, Moller DE, Doebber TW. Peroxisome proliferator-activated
receptor (PPAR)-	 agonism prevents the onset of type 2 diabetes in Zucker
diabetic fatty rats: a comparison with PPAR agonism. Endocrinology
2006;147:4252–4262
28. Kessler MA, Meinitzer A, Petek W, Wolfbeis OS. Microalbuminuria and
borderline-increased albumin excretion determined with a centrifugal
analyzer and the Albumin Blue 580 ﬂuorescence assay. Clin Chem 1997;
43:996–1002
29. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and
puriﬁcation of total lipides from animal tissues. J Biol Chem 1957;226:497–
509
30. Bell GE, Stern JS. Evaluation of body composition of young obese and lean
Zucker rats. Growth 1977;41:63–80
31. Cummings BP, Stanhope KL, Graham JL, Evans JL, Baskin DG, Griffen SC,
Havel PJ. Dietary fructose accelerates the development of diabetes in
UCD-T2DM rats: amelioration by the antioxidant, 	-lipoic acid. Am J
Physiol Regul Integr Comp Physiol 2010;298:R1333–R1342
32. Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M. Systemic admin-
istration of the long-acting GLP-1 derivative NN2211 induces lasting and
reversible weight loss in both normal and obese rats. Diabetes 2001;50:
2530–2539
33. Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB.
Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body
weight and food intake in obese candy-fed rats, whereas a dipeptidyl
peptidase-IV inhibitor, vildagliptin, does not. Diabetes 2007;56:8–15
34. Kanaya AM, Narayan KM. Prevention of type 2 diabetes: data from recent
trials. Prim Care 2003;30:511–526
35. Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, Elahi
D. Clinical review: the extrapancreatic effects of glucagon-like peptide-1
and related peptides. J Clin Endocrinol Metab 2009;94:1843–1852
36. Vahl TP, Tauchi M, Durler TS, Elfers EE, Fernandes TM, Bitner RD, Ellis
KS, Woods SC, Seeley RJ, Herman JP, D’Alessio DA. Glucagon-like
peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal
vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats.
Endocrinology 2007;148:4965–4973
37. Morino K, Petersen KF, Shulman GI. Molecular mechanisms of insulin
resistance in humans and their potential links with mitochondrial dysfunc-
tion. Diabetes 2006;55(Suppl. 2):S9–S15
38. Dunning BE, Gerich JE. The role of 	-cell dysregulation in fasting and
postprandial hyperglycemia in type 2 diabetes and therapeutic implica-
tions. Endocr Rev 2007;28:253–283
39. Ayala JE, Bracy DP, James FD, Julien BM, Wasserman DH, Drucker DJ.
The glucagon-like peptide-1 receptor regulates endogenous glucose pro-
duction and muscle glucose uptake independent of its incretin action.
Endocrinology 2009;150:1155–1164
40. Mueller WM, Gregoire FM, Stanhope KL, Mobbs CV, Mizuno TM, Warden
CH, Stern JS, Havel PJ. Evidence that glucose metabolism regulates leptin
secretion from cultured rat adipocytes. Endocrinology 1998;139:551–558
41. Havel PJ. Update on adipocyte hormones: regulation of energy balance and
carbohydrate/lipid metabolism. Diabetes 2004;53:S143–S148
42. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. -Cell
deﬁcit and increased -cell apoptosis in humans with type 2 diabetes.
Diabetes 2003;52:102–110
B.P. CUMMINGS AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, OCTOBER 2010 2661